文献速递皮肤肿瘤

降低博来霉素剂量的电化学疗法治疗不可切除皮肤肿瘤:InspECT登记库57例分析

Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-12-22

57例患者共147个肿瘤,60天肿瘤完全缓解率为70.1%,患者水平完全缓解率为57.9%;黑色素瘤患者中降低剂量与标准剂量的完全缓解率相同(55%,P=1.00)。结论认为降低剂量可能同样有效,但需前瞻性验证。

要点

  • 降低博来霉素剂量的ECT在不可切除皮肤肿瘤中60天肿瘤完全缓解率达70.1%。
  • 黑色素瘤患者中降低剂量与标准剂量完全缓解率相同(55%,P=1.00)。
  • 局部疼痛是最常见副作用(39%),多为轻度,全身毒性少见。

核心结论

  • 降低博来霉素剂量的电化学疗法可能与传统推荐剂量同样有效。

研究设计与样本

  • 回顾性分析前瞻性维护的InspECT登记库数据,纳入57例患者共147个肿瘤。

主要发现

  • 60天肿瘤水平完全缓解率为70.1%,部分缓解率为16.3%。
  • 患者水平完全缓解率为57.9%,部分缓解率为21.1%。
  • 局部疼痛是最常见副作用(22例,39%),多为轻度;2例出现流感样症状,1例恶心。
  • 黑色素瘤患者中降低剂量组与标准剂量组完全缓解率均为55%(P=1.00)。

关键数值与推荐

  • 肿瘤类型构成:黑色素瘤38.6%,鳞状细胞癌22.8%,基底细胞癌17.5%,乳腺癌7%,卡波西肉瘤7%,其他7.1%。

临床怎么用

  • 肾功能受损或需多次ECT周期的患者可能受益于降低剂量方案。

局限性

  • 研究为回顾性分析,发现需前瞻性确认后才能用于临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Electrochemotherapy (ECT) is currently used to treat unresectable superficial tumours of different histotypes through the combination of cytotoxic chemotherapy and local application of electric pulses. In 2006, a collaborative project defined the ESOPE (European Standard Operating Procedures of Electrochemotherapy) guidelines to standardize the procedure. The International Network for Sharing Practices of Electrochemotherapy (InspECT) aims to refine the ESOPE and improve clinical practice. Limiting patient exposure to systemic chemotherapy would be advisable to ameliorate ECT safety profile. OBJECTIVE: The aim of this study was to evaluate the efficacy and toxicity of ECT with reduced chemotherapy dosages. METHODS: In a retrospective analysis of a prospectively maintained database (InspECT registry), we evaluated the outcome of patients who received ECT with reduced dosages of bleomycin (7500, 10 000 or 13 500 IU/m2 , instead of the standard dose of 15 000 IU/m2 ). Tumour response in melanoma patients was compared with melanoma patients of the InspECT registry who received the standard dose of bleomycin. RESULTS: We identified 57 patients with 147 tumours (melanoma, 38.6%; squamous cell carcinoma, 22.8%; basal cell carcinoma, 17.5%; breast cancer 7%; Kaposi sarcoma 7%; other histotypes, 7.1%). Per-tumour complete response (CR) rate at 60 days was 70.1% (partial, 16.3%); per-patient CR was 57.9% (partial, 21.1%). Local pain was the most frequently reported side-effect (n = 22 patients [39%]), mostly mild; two patients experienced flu-like symptoms, one patient nausea. We observed the same CR rate (55%) in patients with melanoma treated by reduced or conventional bleomycin dosages (P = 1.00). CONCLUSIONS: Electrochemotherapy performed with reduced bleomycin dosages could be as effective as with currently recommended dose. Patients with impaired renal function or candidate to multiple ECT cycles could benefit from a reduced dose protocol. Our findings need prospective confirmation before being adopted in clinical practice.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Rotunno R, Campana LG, Quaglino P, et al. Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry. J Eur Acad Dermatol Venereol. 2017. PMID: 29178483. doi:10.1111/jdv.14708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。